ArticleAIDS research and therapy2026
Pretreatment HIV-1 drug resistance and molecular subtype characteristics among newly diagnosed individuals in Guangxi, China.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe scale-up of antiretroviral therapy (ART) in China has increased concern regarding HIV-1 pretreatment drug resistance (PDR), particularly in Guangxi due to high subtype diversity and population mobility. However, the epidemiology and transmission dynamics of PDR in the region remain insufficiently characterized.
methodsWe assessed PDR prevalence, subtype distribution, and transmission dynamics among ART-naïve individuals in central Guangxi. Between 2018 and 2023, 1,226 newly diagnosed individuals were screened, of whom 1,214 were included after quality control. Drug resistance mutations and subtypes were determined using the Stanford HIV Drug Resistance Database. Molecular transmission networks were constructed using the TN93 model with a genetic distance threshold of < 1.5%.
resultsThe study population was predominantly male (68.8%) and older (57.6% aged > 45 years). Overall, PDR prevalence was 6.0% (73/1,214; 95% CI 4.8-7.4%), ranging annually from 4.3 to 8.3%. CRF01_AE was the dominant subtype (74.3%), followed by CRF07_BC (11.1%) and CRF08_BC (10.3%). Higher PDR prevalence was observed in CRF08_BC (11.1%; 95% CI 6.6-17.9%) and CRF07_BC (8.8%; 95% CI 5.1-15.0%). Network analysis identified 102 transmission clusters comprising 612 sequences (50.4%), including two clusters containing ≥ 2 individuals sharing identical NNRTI resistance mutations, all linked through heterosexual transmission.
conclusionsIn central Guangxi, HIV-1 PDR remains moderate, primarily driven by NNRTI-associated mutations, with limited evidence of clustering within transmission networks. These findings highlight the need for continued resistance surveillance and optimization of first-line ART regimens. Trial registration Not applicable. This retrospective cohort study was not registered as a clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.